Analysts expect Pharming revenue to rise 21% in the third quarter
Based on a three-analyst consensus compiled by LSEG, Pharming Group revenue is seen up 21% with earnings of 2 cents a share. Results due October 27.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Leiden-based Pharming Group N.V. is set to report results on October 27 for the period ending September 30, 2026. The LSEG consensus, drawn from three analysts, points to revenue of $117.733 million, up 21.0% from $97.3 million a year earlier. The average earnings forecast stands at 2 cents per share.
The average rating on the stock is "strong buy". All six recommendations are positive, with "strong buy" or "buy" and no "hold", "sell" or "strong sell" ratings. The mean earnings estimate has not changed over the past three months. Source: Earnings Preview.
why it matters
For the broader market this is a routine pre-earnings benchmark, since one smaller company's report rarely moves major indices. Attention will center on actual revenue and profit versus consensus and on whether analysts revise their forecasts. Estimates that have stayed flat for three months suggest no fresh expectations have emerged.
tags
instruments
sources
- Pharming Group N.V. expected to post earnings of 2 cents a share — Earnings Preview, 23 October 2026 at 06:02 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗